Lincoln Pharma Share Price

Lincoln Pharmaceuticals Limited is a leading pharmaceutical company in India, engaged in the manufacturing, marketing, and distribution of a wide range of pharmaceutical products. The company offers products in therapeutic areas including anti-infective, respiratory system, gynecology, cardio and CNS, anti-diabetic, anti-malaria, pain management, and cosmo-derma. Lincoln Pharmaceuticals has carved a distinct niche in the global pharmaceutical landscape, committed to innovation, quality, and expansion. The Lincoln Pharmaceuticals share price on the NSE and BSE is a reflection of how market participants respond to a company’s performance and broader business developments within its industry. It captures the sentiment of the investors based on financial results, operational updates, macroeconomic factors, and trends specific to sectors. Movements in the share price͏ reveal how the market evaluates the company’s current position and its future prospects, making ͏it a key indicator of market perception across various industries.

Market sentiment around the Lincoln Pharmaceuticals stock price often mirrors shifts in domestic pharmaceutical demand, export trends, and investor views on the healthcare sector’s growth prospects. Factors such as the pace of new product launches, competitive intensity from domestic and international players, regulatory changes from the CDSCO, and government policies on healthcare influence near-term market valuation and medium-term earnings forecasts. All these factors must be closely monitored to have an idea about the Lincoln Pharmaceuticals stock price movements.

Lincoln Pharmaceuticals live share price provides real-time information about the last price traded, bid price, ask price, and volume traded. These indicators represent trading activity and liquidity and the reaction of investors to corporate announcements, quarterly results, and sector news. Constant monitoring of Lincoln Pharmaceuticals live price helps observe short-term price fluctuations and understand how the stock is moving in relation to the broader market.

Furthermore, monitoring the Lincoln Pharmaceuticals share price today helps investors understand real-time market sentiment, price volatility, and trading behaviour. It allows market participants to evaluate short-term performance, identify possible entry or exit points, and respond to news, quarterly results or sector trends that may affect the company’s valuation and overall investment outlook.

Lincoln Pharmaceuticals Limited Company Fundamentals

a. Company Background

Lincoln Pharmaceuticals Limited was incorporated in 1995. The company’s registered office is located in Ahmedabad, Gujarat, India. The company was established as a partnership firm on January 18, 1979, by Mr. Rajni G. Patel and Mr. Hasmukhbhai I. Patel with other fellow partners. The company converted into a public limited company in January 1995. Lincoln Pharmaceuticals’ primary activity involves the manufacturing, marketing, and distribution of pharmaceutical products, getting its products manufactured on a loan licence basis from 1979 to 1982 before setting up its own manufacturing facilities at Naroda, Gujarat for manufacturing tablets, capsules, liquid and powder syrups, and ointments. Over the years, Lincoln Pharmaceuticals has significantly expanded its product portfolio and market presence, getting listed on the Bombay Stock Exchange (BSE) in 1996. The company also got listed on the National Stock Exchange (NSE) in December 2015. It operates in a regulated environment, with pricing and manufacturing governed by the Central Drugs Standard Control Organization (CDSCO). The company has consistently focused on enhancing its product offerings and healthcare access to meet the growing demand for quality medicines, with a vision to be a leading force in global healthcare by revolutionizing medicine through relentless research.

b. Product Lines

• Anti-infective products for treatment of bacterial and viral infections

• Respiratory system medications for asthma, bronchitis, and related conditions

• Gynecology products for women’s health and reproductive care

• Cardio and CNS (central nervous system) medications for heart conditions and neurological disorders

• Anti-diabetic drugs for diabetes management

• Anti-malarial medications for malaria treatment and prevention

• Pain management products including analgesics and anti-inflammatory drugs

• Cosmo-derma products for dermatological and cosmetic applications

• Anti-cold, antibiotic, otolaryngology, and gastro medications

• Anti-fungal, corticosteroid, and anti-hypertensive products

c. Company Revenue Model

• Primary revenue from the sale of pharmaceutical formulations to domestic and international markets

• Volume-driven revenue based on quantity of drugs sold to hospitals, pharmacies, and distributors

• Pricing determined by regulatory frameworks (NPPA) and competition, affecting overall revenue generation

• Revenue from exports to international markets through distribution networks and partnerships

• Expanding geographical footprint contributing to new customer acquisition and revenue streams

• Focus on increasing product portfolio across multiple therapeutic segments to drive higher sales

• Investment in manufacturing facilities and quality certifications to enhance product offerings

• Seasonal variations in demand for certain therapeutic categories affecting revenue patterns throughout the year

• Government policy changes on drug pricing and healthcare spending influencing revenue stability

d. Geographic Presence

• Strong presence across India with manufacturing facilities at Naroda, Gujarat

• Domestic market expansion covering 80% of the Indian market through extensive distribution networks

• Presence in international markets through exports of pharmaceutical products

• Registered office and corporate headquarters located in Ahmedabad, Gujarat

• Digital platform enabling customer acquisition across domestic and international markets

• Operations primarily concentrated in India, serving domestic markets across all states

e. Key Milestones

• 1979: Established as a partnership firm on January 18 by Mr. Rajni G. Patel, Mr. Hasmukhbhai I. Patel, and other partners

• 1995: Converted into a public limited company in January

• 1996: Listed on Bombay Stock Exchange (BSE)

• 2000: By this year, company had expanded its manufacturing capabilities and product portfolio

• 2004: Installed a 600 KVA windmill for captive power generation

• 2015: Listed on National Stock Exchange (NSE) in December

• 2015-16: Installed an additional 2.1 MW windmill

• 2024: Received establishment approval for new product categories and continued expansion

f. Industry Perspective

Lincoln Pharmaceuticals Limited operates in the pharmaceutical industry. Globally, the pharmaceutical market was valued at approximately USD 1.5 trillion in 2025 and is projected to grow at a compound annual growth rate (CAGR) of 3-6% through 2026. In India, the pharmaceutical market was valued at approximately USD 66.66 billion in 2025 and is projected to reach USD 88.86 billion by 2030, growing at a CAGR of 5.92% during the forecast period (2025-2030). The domestic pharmaceutical market, valued at around USD 60 billion, is expected to double to about USD 130 billion by 2030. The sector’s annual turnover reached ₹4.72 lakh crore in FY25. India is the third-largest pharmaceutical market globally by volume, with pharma exports expected to cross USD 30 billion. The domestic formulations market is projected to grow at an 8-10% CAGR, with export growth forecasted at 10%. The government aims to increase healthcare spending and access, with the AB-PMJAY scheme receiving increased allocation. Key challenges include regulatory compliance, pricing pressures from the National Pharmaceutical Pricing Authority (NPPA), intense competition from domestic and multinational players, and the upcoming Drugs, Medical Devices and Cosmetics Bill, 2023.

Lincoln Pharmaceuticals Limited Stock Market Presence: Listings & Index Representation

Lincoln Pharmaceuticals is actively traded on India’s principal equity markets, with its shares listed on the National Stock Exchange of India (NSE) under the symbol LINCOLN and on the Bombay Stock Exchange (BSE) with the scrip code 531633. The company’s ISIN number is INE405C01035, with a face value of ₹10 per share. Its listing on both exchanges ensures that the Lincoln Pharmaceuticals price is accessible to a wide investor base, encompassing both retail and institutional market participants. The company was listed on BSE in 1996 and on NSE in December 2015. The company forms part of several benchmark indices that represent broad market segments. Lincoln Pharmaceuticals is included in indices such as BSE Healthcare, BSE SmallCap, BSE 500, BSE AllCap, and Nifty 500 on the NSE. Being represented in multiple indices enhances the visibility and liquidity of the Lincoln Pharmaceuticals stock price, as index tracking funds and exchange traded strategies often adjust allocations in line with constituent revisions. It also allows investors to benchmark the company’s stock performance relative to broader market trends and peer groups, facilitating cross sectional comparisons within India’s pharmaceutical landscape. The inclusion of Lincoln Pharmaceuticals in these indices reflects its market capitalisation and trading depth, which are key factors market participants consider when evaluating long term investment prospects and the responsiveness of the stock price to corporate and industry developments.

Lincoln Pharmaceuticals Limited Stock Performance and Share Price History

The Lincoln Pharmaceuticals price has exhibited significant volatility over the past decade, shaped by the company’s growth in the pharmaceutical sector and broader industry cycles. The Lincoln Pharmaceuticals share price recorded a 1-year total return of approximately 8.15% as of April 2026, outperforming the Nifty 50 which provided a return of -2.65% during the same period. The Lincoln Pharmaceuticals share price delivered a 3-year total return of 14.45%, demonstrating positive long-term wealth creation. The Lincoln Pharmaceuticals share price reached a 52-week high of ₹677.00 (BSE) and ₹679.45 (NSE) on February 13, 2026, and a 52-week low of ₹439.95 on January 28, 2026, indicating a wide trading range and substantial price fluctuations of approximately ₹239 from peak to trough. The Lincoln Pharmaceuticals share price recorded a strong rally in earlier years, while the subsequent period has seen the Lincoln Pharmaceuticals stock price consolidate near its highs. The Lincoln Pharmaceuticals share price has shown a 1-month return of approximately 2-3% and a 3-month return of around 1.24 times beta-adjusted as of April 2026, indicating recent stability.

The Lincoln Pharmaceuticals stock price has been particularly responsive to quarterly earnings releases and corporate announcements. When the company reported a 37.70% year-on-year surge in consolidated net profit to ₹28.60 crore in Q3 FY2025-26, the Lincoln Pharmaceuticals stock price showed a positive reaction. The Lincoln Pharmaceuticals price has shown a pattern of positive momentum in quarters when the company’s earnings exceeded expectations, while periods of earnings moderation or concerns over regulatory headwinds have contributed to consolidation in the Lincoln Pharmaceuticals stock price. Corporate developments, including strategic announcements such as capacity expansions, new product launches in various therapeutic segments, and the installation of windmill capacity for captive power generation, have also influenced short-term fluctuations in the Lincoln Pharmaceuticals price. The Lincoln Pharmaceuticals share price has shown a 5-year CAGR of approximately 22% and a 10-year CAGR of 15% according to data, reflecting the volatility in the stock. The Lincoln Pharmaceuticals share price has shown a 10-year aggregate net profit that reflects the company’s sustained profitability over the long term. The Lincoln Pharmaceuticals share price reached its 52-week high of ₹677.00 before declining to its 52-week low of ₹439.95, reflecting the volatility inherent in the pharmaceutical space. The Lincoln Pharmaceuticals share price has shown a year-to-date return of approximately -1% as of April 2026, indicating pressure in the current fiscal year. Comprehending these patterns in the Lincoln Pharmaceuticals share price is instrumental for investors seeking to contextualise long term performance trends vis à vis short term price dynamics, as the Lincoln Pharmaceuticals price movements illustrate how industry fundamentals, regulatory cycles, and investor expectations converge in market pricing.

The Lincoln Pharmaceuticals price has shown distinct seasonal patterns over the past decade. In terms of annual performance, the Lincoln Pharmaceuticals price delivered its strongest returns in earlier years when the pharmaceutical sector was experiencing robust growth. The Lincoln Pharmaceuticals share price has demonstrated that the stock tends to perform better in periods of strong domestic pharmaceutical demand and favourable export conditions, while underperforming during phases of regulatory uncertainty and intense competition.

Lincoln Pharmaceuticals Limited Investor Relevance and Role in Portfolio

Lincoln Pharmaceuticals holds a significant position for portfolio investors who seek exposure to India’s pharmaceutical sector with a focus on domestic formulations and export markets. The company’s diversified product portfolio across multiple therapeutic segments and its strong manufacturing capabilities aligns it with investment strategies that value manufacturing scale and product innovation. The Lincoln Pharmaceuticals share price often mirrors how these themes resonate with investor portfolios, whereby both thematic and sector specific funds monitor regulatory approvals, drug pricing trends, and healthcare spending indicators when evaluating allocation decisions.

Institutional stakeholders play a significant role in Lincoln Pharmaceuticals’ ownership profile, with notable long term investment entities such as Motilal Oswal BSE Healthcare ETF, Bandhan BSE Healthcare Index Fund, American Century ETF Trust – Avantis Emerging Markets Equity ETF, and DFA Investment Dimensions Group Inc. – Emerging Markets Core Equity 2 Portfolio among key shareholders identified in institutional holdings data. Mutual fund holders of Lincoln Pharmaceuticals encompass those that seek healthcare and pharmaceutical exposure. As of December 2025, promoters hold 49.78% of the company, Mutual Funds hold approximately 0.03-0.05%, Foreign Institutional Investors (FIIs) hold 4.70%, Domestic Institutional Investors (DIIs) hold 0.01%, Insurance companies hold 0%, and Retail holds approximately 45.52% of Lincoln Pharmaceuticals. Institutional investors (FII + DII) together hold approximately 4.71% stake. Institutional stakes have steadily risen, with FII and DII holdings increasing from under 1% in March 2022 to 5.2% by September 2024. These investors represent a blend of domestic and international perspectives that contribute to the stock’s market liquidity and visibility within broader investment frameworks.

The beta analysis of Lincoln Pharmaceuticals across multiple time periods highlights its changing volatility in relation to the overall market. Based on data, the long-term beta stands at approximately 1.78, indicating that the stock is generally more volatile than the broader market over an extended period. In short-term analysis, beta values over the 1-month range of 1.85 show higher sensitivity to recent market fluctuations, while the 3-month range of 1.24 indicates moderate responsiveness, and the 6-month range of 1.43 suggests continued higher volatility. Weekly data reveals beta over a one-year period of 1.78 showing the stock’s high sensitivity to weekly market changes, with the three-year beta of 1.52 indicating sustained higher volatility. The average weekly movement of Lincoln Pharmaceuticals stock is approximately 7.5%, compared to the Indian market average of 5-6%, indicating higher volatility than the broader market. The stock’s weekly volatility of approximately 7% has been stable over the past year, while its three-month price volatility is lower at around 3%. The mean and standard deviation values for various time ranges are: for the 1-month daily range, mean values vary with standard deviations in the 2-3 range; for the 3-month daily range, mean values of around 580-600 with standard deviations of 1.2-1.4; for the 1-year weekly range, mean values of approximately 560-620 with standard deviations of 2.0-2.5. The Lincoln Pharmaceuticals share price has shown periods of heightened responsiveness to sector-specific news and quarterly earnings releases. The Lincoln Pharmaceuticals stock price’s beta reflects that the company’s established market position and diversified product portfolio may provide some stability, though the pharmaceutical sector remains sensitive to regulatory changes and drug price fluctuations.

Lincoln Pharmaceuticals Limited Sectoral Relevance and Peer Positioning

The sector relevance of Lincoln Pharmaceuticals is anchored in its role within the broader Indian pharmaceutical industry, where it competes with other diversified drug manufacturing companies. As part of this industry, the company’s strategic positioning connects formulations across multiple therapeutic categories serving healthcare needs across domestic and international markets. Competitors in the pharmaceutical segment include companies such as Sun Pharmaceutical Industries Limited, Divi’s Laboratories Limited, Torrent Pharmaceuticals Limited, Cipla Limited, Aarey Drugs & Pharmaceuticals Ltd., Aarti Pharmalabs Ltd., Kilitch Drugs (India) Limited, Kopran Limited, Themis Medicare Limited, Ajanta Pharma, Eris Lifesciences, Caplin Point Labs, Senores Pharmaceuticals, and Link Pharmachem. Firms with parallels in either product portfolio scale or manufacturing capabilities are often referenced when evaluating relative performance and operational positioning within the sector.

In valuation terms, factors like the Lincoln Pharmaceuticals P/E ratio have shown variations over different periods. The mean historical P/E ratio over the last five years has varied, with the current P/E ratio of approximately 12.47 to 14.04 times representing a 55% discount to its peers’ median range of 27.50 times. The Lincoln Pharmaceuticals P/E ratio has shown significant fluctuations, with the ratio at 7.23x in 2021, 8.98x in 2022, 9.30x in 2023, 13.42x in 2024, and 14.04x in 2025, reflecting changing investor perceptions of the company’s earnings potential.

Similarly, the Lincoln Pharmaceuticals EPS narrative has shown variation according to how operational performance aligns with industry demand cycles and cost structures. Structural gains from capacity expansion and new product launches supported directional improvement in earnings per share during favourable conditions, while cyclical headwinds from raw material inflation and regulatory changes have moderated EPS momentum. Lincoln Pharmaceuticals earnings have shown a trajectory that responded to both revenue growth and margin pressures over the analysed period. Lincoln Pharmaceuticals market cap has fluctuated in line with investor perceptions of the company’s growth potential in a competitive and evolving pharmaceutical market.

Over the last five years, the market capitalisation of Lincoln Pharmaceuticals has followed a pattern of significant growth. From fiscal year 2020 to 2025, the company’s market cap showed an increasing trend, reflecting strong investor confidence during the pharmaceutical sector boom. The market cap increased from ₹2,676 crore in 2020 to ₹4,494 crore in 2021, ₹6,230 crore in 2022, ₹6,784 crore in 2023, and reached a peak of ₹11,725 crore in 2024. The year-end market cap stood at ₹12,299.5 crore in 2023 according to TickJournal data, with a 71.42% increase. According to current data, market cap is approximately ₹1,211.60 crore to ₹1,235 crore as of April 2026. This growth reflects investor confidence in the company’s strong product portfolio, manufacturing capabilities, and the overall growth of the pharmaceutical sector.

The earnings history of Lincoln Pharmaceuticals over the past five years has been characterised by a period of consistent growth. Net income showed a generally increasing trend, with reported net profit rising from ₹69.36 crore in earlier years to ₹72.90 crore, ₹93.30 crore in FY2024, and ₹82.35 crore in FY2025 (a 11.74% decrease from FY2024). The 10-year aggregate net profit reflects the company’s sustained profitability over the long term. Quarterly performance showed a 37.70% year-on-year surge in consolidated net profit to ₹28.60 crore in Q3 FY2025-26. Revenue in Q3 FY2025-26 stood at ₹166.32 crore. Sales increased from ₹646 crore in FY2024-25 with a 7.35% growth. Total income in FY2024-25 was ₹53,852 lakhs (approximately ₹538.52 crore), compared to ₹46,396 lakhs (approximately ₹463.96 crore) in the previous year, representing a growth of 16%. This consistent earnings performance reflects the impact of strong domestic demand, export growth, and operational efficiency on the company’s profitability.

The Earnings Per Share (EPS) history for Lincoln Pharmaceuticals has shown an improving trend over the past decade. The diluted EPS growth rate has shown variation, with EPS at ₹31.08 in 2021, ₹34.63 in 2022, ₹36.40 in 2023, ₹46.58 in 2024, and ₹41.11 in 2025. According to other sources, TTM EPS stands at approximately ₹43.85 to ₹44.0. Over a five-year period, the company demonstrated consistent improvement in EPS, with average earnings per share growth of approximately 10-15% per year. The highest EPS was recorded in FY2024 at ₹46.58, while recent quarters have shown some moderation in per-share earnings due to increased competition and regulatory pressures.

The Price-to-Earnings (P/E) ratio history of Lincoln Pharmaceuticals has shown fluctuations over the five-year period. At the end of recent fiscal years, the P/E ratio varied, with 2020 at 5.2x, 2021 at 7.23x, 2022 at 8.98x, 2023 at 9.30x, 2024 at 13.42x, and 2025 at 14.04x. The mean historical P/E ratio over the last five years has been around 10-12 times. The current P/E ratio stands at a significant discount to the industry peer median of 27.50 times, reflecting that investor expectations remain anchored to near-term earnings headwinds despite the company’s strong growth trajectory. The Lincoln Pharmaceuticals share price has been influenced by these valuation metrics. The Lincoln Pharmaceuticals stock price continues to be evaluated in the context of its earnings potential and market position.

Summary

Lincoln Pharmaceuticals is a leading pharmaceutical formulations company in India listed on both the NSE and BSE, where the Lincoln Pharmaceuticals share price reflects domestic healthcare spending cycles, drug pricing regulations, and export demand within the pharmaceutical sector. Its representation in multiple stock indices supports market visibility, while investor interest is shaped by earnings trends, valuation narratives, and broader healthcare access themes. Within the sector, the company’s competitive context and earnings dynamics provide key perspectives on its role in India’s pharmaceutical market.